suramin has been researched along with Cancer of Ovary in 8 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Regular pharmacokinetic sampling of plasma and ascites fluid was carried out." | 2.69 | Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. ( Baars, JP; Beijnen, JH; Dubbelman, R; Moolenaar, WH; Rodenhuis, S; Westermann, AM, 2000) |
| "Suramin was administered in a fashion that is associated with durable objective disease response in patients with hormonally resistant metastatic prostate cancer." | 2.67 | Suramin in advanced platinum-resistant ovarian cancer. ( Bostick-Bruton, F; Cooper, MR; LaRocca, RV; Myers, CE; Reed, E, 1992) |
| "In large part, ovarian cancer's lethality is due to the fact that most women are diagnosed with disease that is widespread throughout the abdomen and pelvis." | 2.39 | Promising new developments in the systemic treatment of ovarian cancer. ( Reed, E, 1994) |
| "Suramin inhibited the ovarian cancer cell proliferation in vitro in a dose-dependent manner between 10 and 80 microM, showing the IC50 of 29 microM." | 1.29 | Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II). ( Hirata, J; Hisano, A; Kikuchi, Y; Kita, T; Nagata, I; Tode, T, 1995) |
| "The results indicate that these ovarian cancer cell lines can produce bFGF as well as other members of the FGF family of genes and have the ability to respond to bFGF." | 1.29 | Basic fibroblast growth factor and receptor expression in human ovarian cancer. ( Crickard, K; Crickard, U; Eidsvoog, K; Gross, JL; Herblin, WF; Lele, S; Yoonessi, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luquain, C | 1 |
| Singh, A | 1 |
| Wang, L | 1 |
| Natarajan, V | 1 |
| Morris, AJ | 1 |
| Kalli, KR | 1 |
| Bradley, SV | 1 |
| Fuchshuber, S | 1 |
| Conover, CA | 1 |
| Bose, CK | 1 |
| Reed, E | 2 |
| Kikuchi, Y | 1 |
| Hirata, J | 1 |
| Hisano, A | 1 |
| Tode, T | 1 |
| Kita, T | 1 |
| Nagata, I | 1 |
| Crickard, K | 1 |
| Gross, JL | 1 |
| Crickard, U | 1 |
| Yoonessi, M | 1 |
| Lele, S | 1 |
| Herblin, WF | 1 |
| Eidsvoog, K | 1 |
| Westermann, AM | 1 |
| Dubbelman, R | 1 |
| Baars, JP | 1 |
| Moolenaar, WH | 1 |
| Beijnen, JH | 1 |
| Rodenhuis, S | 1 |
| Cooper, MR | 1 |
| LaRocca, RV | 1 |
| Bostick-Bruton, F | 1 |
| Myers, CE | 1 |
2 reviews available for suramin and Cancer of Ovary
| Article | Year |
|---|---|
Follicle stimulating hormone receptor (FSHR) antagonist and epithelial ovarian cancer (EOC).
Topics: Animals; Antineoplastic Agents; Female; Humans; Meta-Analysis as Topic; Molecular Weight; Neoplasms, | 2007 |
Promising new developments in the systemic treatment of ovarian cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Female; Granulocyte Colo | 1994 |
2 trials available for suramin and Cancer of Ovary
| Article | Year |
|---|---|
Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Topics: Adult; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Dru | 2000 |
Suramin in advanced platinum-resistant ovarian cancer.
Topics: Adult; Aged; Carboplatin; Cisplatin; Drug Evaluation; Drug Resistance; Female; Humans; Middle Aged; | 1992 |
4 other studies available for suramin and Cancer of Ovary
| Article | Year |
|---|---|
Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Base Sequence; Cell Division; Female; Humans | 2003 |
Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cells; E | 2004 |
Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
Topics: Animals; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumo | 1995 |
Basic fibroblast growth factor and receptor expression in human ovarian cancer.
Topics: Base Sequence; Blotting, Western; Cell Division; DNA, Neoplasm; Female; Fibroblast Growth Factor 2; | 1994 |